1. Home
  2. DG vs ROIV Comparison

DG vs ROIV Comparison

Compare DG & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dollar General Corporation

DG

Dollar General Corporation

HOLD

Current Price

$130.97

Market Cap

27.2B

ML Signal

HOLD

Logo Roivant Sciences Ltd.

ROIV

Roivant Sciences Ltd.

HOLD

Current Price

$34.11

Market Cap

25.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DG
ROIV
Founded
1939
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Department/Specialty Retail Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.2B
25.1B
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
DG
ROIV
Price
$130.97
$34.11
Analyst Decision
Buy
Strong Buy
Analyst Count
21
9
Target Price
$139.60
$28.94
AVG Volume (30 Days)
2.0M
7.1M
Earning Date
06-02-2026
05-28-2026
Dividend Yield
2.07%
N/A
EPS Growth
34.05
N/A
EPS
4.49
N/A
Revenue
$42,724,369,000.00
$8,260,000.00
Revenue This Year
$7.14
N/A
Revenue Next Year
$4.17
$744.61
P/E Ratio
$29.16
N/A
Revenue Growth
5.20
N/A
52 Week Low
$95.11
$12.54
52 Week High
$158.23
$37.97

Technical Indicators

Market Signals
Indicator
DG
ROIV
Relative Strength Index (RSI) 62.88 41.14
Support Level $115.31 $33.01
Resistance Level $132.31 $37.59
Average True Range (ATR) 3.86 1.19
MACD 0.85 -0.38
Stochastic Oscillator 83.84 15.53

Price Performance

Historical Comparison
DG
ROIV

About DG Dollar General Corporation

Since its beginning in 1939, Dollar General has grown to become the largest dollar store operator in the United States, with more than 20,000 small-box discount stores across 48 states. The firm generated over $42 billion in fiscal 2025 sales. The retailer maintains a heavy concentration of stores in rural and low-income markets underserved by big-box retailers. It's 11,000 stock-keeping units, including 2,000 priced at $1 or less, span consumables (82% of sales), seasonal items (10%), home products (5%), and apparel (3%). More than 20% of sales are derived from private label.

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Share on Social Networks: